AIM

#4000
AIM ImmunoTech Inc.
0.9076
-8.77%
Setor:
Base:
Moeda do lucro:
Faixa diária
0.8747
0.9252
Faixa anual
0.7653
20.3500
Mudança diária
-8.77%
Mudança mensal
-24.99%
Mudança em 6 meses
-64.12%
Mudança anual
-89.32%
Fechamento anterior
0.9948
Open
0.8851
Bid
Ask
Low
0.8747
High
0.9252
Volume
20
Open full chart

Financials

Overview Relatórios Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.9 M
  • Employee 23
  • Founded N/A
  • CEO N/A
  • Website www.aimimmuno.com
  • Headquarter Delaware, United States
  • FIGI BBG000JL6Z80
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.16
Price to sales ratio
18.46
Dividends per share
—
Dividend yield %
—

AIM ImmunoTech Inc

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.

Notícias